Form 4: United Therapeutics EVP Paul Mahon Exercises Options and Sells Shares Under 10b5-1 Plan
SEC Form 4
Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares of common stock on May 1, 2025, under a pre-arranged 10b5-1 trading plan.
Summary
- On May 1, 2025, Paul Mahon, the EVP & General Counsel of United Therapeutics, exercised stock options for 11,000 shares at a price of $117.76 per share.
- Following the exercise, Mahon sold a total of 11,191 shares of common stock in multiple transactions at prices ranging from $295.1206 to $303.38.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on December 24, 2024.
- After these transactions, Mahon beneficially owns 36,781 shares of United Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
This filing is a routine disclosure of insider transactions. Executives often use 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. This is a common practice among publicly traded companies.
Comparison to Industry Standards
- Executive stock option exercises and sales are common across the pharmaceutical and biotechnology industries.
- Companies like Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings from their executives.
- The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.
Stakeholder Impact
- The transactions have a minimal direct impact on stakeholders.
- Shareholders may see a slight dilution of equity due to the option exercise, but the subsequent sale is unlikely to significantly affect the stock price.
Key Dates
| Date | Description |
|---|---|
| 03/15/2021 | Stock options exercisable date |
| 12/24/2024 | Date of pre-arranged 10b5-1 plan |
| 03/15/2027 | Stock options expiration date |
| 05/01/2025 | Date of stock option exercise and share sales |
| 05/02/2025 | Date of signature |
Keywords
United Therapeutics, UTHR, Paul Mahon, Stock Options, SEC Form 4, 10b5-1 Plan, Insider Trading, Executive Compensation, Share Sale
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.